Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VYN201 Gel in the Treatment of Non-Segmental Vitiligo
NCT06493578Phase 2Terminated
- Sponsor
- Vyne Therapeutics
- Start
- Jun 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of repibresib in Vitiligo (4 arms), sponsored by Vyne Therapeutics. Primary endpoint: Efficacy of VYN201 compared to vehicle at 24 weeks. Started Jun 2024; status: terminated.
02
Drugs
repibresib
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT06493578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06493578.